The round will fund a “one-and-done” treatment for a rare kidney condition that its CEO says can address concerns patients have with therapies from Alnylam and Novo Nordisk.

Carlyle Group's acquisition of bluebird bio for $3 per share offers a potential but unlikely $600 million sales milestone by 2027. See why BLUE stock is a Hold.

Through his two-year, $3.97 million contact Travis Homer didn't do much for the Chicago Bears offense but they're bringing him back for a third season.

A New Mexico court has granted a temporary restraining order against the release of certain records related to the ...

Village Roadshow, producer and financier of The Matrix, Joker and Lego movie franchises, filed for bankruptcy protection amid ...

A Santa Fe doctor has sensationally claimed that the former classical pianist, 65, had called him the day after police say ...